istradefylline vs VG081821AC

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Parkinson's Disease

Shared mechanism: adenosine A2A · full Parkinson's Disease pipeline

istradefylline · Nourianz

Marketed by Kyowa Kirin

Approved in Parkinson's Diseasesmall molecule
Partial signal

NCT01968031 · Phase 3 · completed

This randomized, double-blind, placebo-controlled global Phase 3 trial treated 609 patients with moderate to severe Parkinson's disease and wearing-off on levodopa with istradefylline 20 mg, 40 mg or placebo for 12 weeks. The primary endpoint was change from baseline in daily OFF hours at week 12. The sponsor reports a trend toward less OFF time but no statistically significant difference from placebo for either dose, so the primary was missed. The registry posts median OFF hours by visit but no test. Source: the sponsor's topline release, which names NCT01968031.

Result from the sponsor's press release; the release gives no effect estimate or p-value.

Reported efficacy

To establish the efficacy of a 20 mg/d dose of istradefylline for reducing the percentage of OFF time in patients with advanced Parkinson's disease (PD) treated with levodopa/carbidopa.: Placebo-corrected reduction in daily OFF time at endpoint: 4.6% (equivalent to 0.7 hours), P=0.03, favoring istradefylline 20mg/day over placebo. (met)

Result source: NCT00199407

VG081821AC

Developed by Vimgreen Pharmaceuticals

Phase 2/3 in Parkinson's Diseasesmall molecule
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: October 2027 · NCT07725562 (registry estimate)

No aligned efficacy figure on record for this race.

Results for Parkinson's Disease

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointistradefyllineVG081821AC
OFF time, change4 vs 4.2−0.2 vs placebo20 mg/Day · wk 12 · n 194NCT01968031
7 other results
  • 3.8 vs 4.3 20 mg/Day · wk 10 · n 194 · Phase 3 · primary NCT01968031
  • 3.8 vs 4.2 20 mg/Day · wk 6 · n 194 · Phase 3 · primary NCT01968031
  • 4.3 vs 4.8 20 mg/Day · wk 2 · n 194 · Phase 3 · primary NCT01968031
  • 3.8 vs 4.2 40 mg/Day · wk 12 · n 200 · Phase 3 · primary NCT01968031
  • 3.5 vs 4.3 40 mg/Day · wk 10 · n 200 · Phase 3 · primary NCT01968031
  • 3.8 vs 4.2 40 mg/Day · wk 6 · n 200 · Phase 3 · primary NCT01968031
  • 4.1 vs 4.8 40 mg/Day · wk 2 · n 200 · Phase 3 · primary NCT01968031
—Trial running · NCT07725562
ON time without troublesome dyskinesia, change10.7 vs 10.1+0.6 vs placebo20 mg/Day · wk 12 · n 194NCT01968031
7 other results
  • 10.7 vs 10.1 20 mg/Day · wk 10 · n 194 · Phase 3 · secondary NCT01968031
  • 10.7 vs 10.2 20 mg/Day · wk 6 · n 194 · Phase 3 · secondary NCT01968031
  • 10.2 vs 9.9 20 mg/Day · wk 2 · n 194 · Phase 3 · secondary NCT01968031
  • 10.5 vs 10.1 40 mg/Day · wk 12 · n 200 · Phase 3 · secondary NCT01968031
  • 10.5 vs 10.1 40 mg/Day · wk 10 · n 200 · Phase 3 · secondary NCT01968031
  • 10.5 vs 10.2 40 mg/Day · wk 6 · n 200 · Phase 3 · secondary NCT01968031
  • 10.5 vs 9.9 40 mg/Day · wk 2 · n 200 · Phase 3 · secondary NCT01968031
—Trial running · NCT07725562
UPDRS Part III, change19.7 vs 19.4+0.3 vs placebo20 mg/Day · wk 12 · n 194NCT01968031
7 other results
  • 19.4 vs 19.2 20 mg/Day · wk 10 · n 194 · Phase 3 · secondary NCT01968031
  • 20.2 vs 19.9 20 mg/Day · wk 6 · n 194 · Phase 3 · secondary NCT01968031
  • 20.8 vs 20.1 20 mg/Day · wk 2 · n 194 · Phase 3 · secondary NCT01968031
  • 19.6 vs 19.4 40 mg/Day · wk 12 · n 200 · Phase 3 · secondary NCT01968031
  • 19.9 vs 19.2 40 mg/Day · wk 10 · n 200 · Phase 3 · secondary NCT01968031
  • 20.2 vs 19.9 40 mg/Day · wk 6 · n 200 · Phase 3 · secondary NCT01968031
  • 20.7 vs 20.1 40 mg/Day · wk 2 · n 200 · Phase 3 · secondary NCT01968031
—Trial running · NCT07725562
MDS-UPDRS Part II, change—Not posted · NCT00955526—Trial running · NCT07725562

OFF time, change

istradefylline
4 vs 4.2−0.2 vs placebo20 mg/Day · wk 12 · n 194NCT01968031
7 other results
  • 3.8 vs 4.3 20 mg/Day · wk 10 · n 194 · Phase 3 · primary NCT01968031
  • 3.8 vs 4.2 20 mg/Day · wk 6 · n 194 · Phase 3 · primary NCT01968031
  • 4.3 vs 4.8 20 mg/Day · wk 2 · n 194 · Phase 3 · primary NCT01968031
  • 3.8 vs 4.2 40 mg/Day · wk 12 · n 200 · Phase 3 · primary NCT01968031
  • 3.5 vs 4.3 40 mg/Day · wk 10 · n 200 · Phase 3 · primary NCT01968031
  • 3.8 vs 4.2 40 mg/Day · wk 6 · n 200 · Phase 3 · primary NCT01968031
  • 4.1 vs 4.8 40 mg/Day · wk 2 · n 200 · Phase 3 · primary NCT01968031
VG081821AC
—Trial running · NCT07725562

ON time without troublesome dyskinesia, change

istradefylline
10.7 vs 10.1+0.6 vs placebo20 mg/Day · wk 12 · n 194NCT01968031
7 other results
  • 10.7 vs 10.1 20 mg/Day · wk 10 · n 194 · Phase 3 · secondary NCT01968031
  • 10.7 vs 10.2 20 mg/Day · wk 6 · n 194 · Phase 3 · secondary NCT01968031
  • 10.2 vs 9.9 20 mg/Day · wk 2 · n 194 · Phase 3 · secondary NCT01968031
  • 10.5 vs 10.1 40 mg/Day · wk 12 · n 200 · Phase 3 · secondary NCT01968031
  • 10.5 vs 10.1 40 mg/Day · wk 10 · n 200 · Phase 3 · secondary NCT01968031
  • 10.5 vs 10.2 40 mg/Day · wk 6 · n 200 · Phase 3 · secondary NCT01968031
  • 10.5 vs 9.9 40 mg/Day · wk 2 · n 200 · Phase 3 · secondary NCT01968031
VG081821AC
—Trial running · NCT07725562

UPDRS Part III, change

istradefylline
19.7 vs 19.4+0.3 vs placebo20 mg/Day · wk 12 · n 194NCT01968031
7 other results
  • 19.4 vs 19.2 20 mg/Day · wk 10 · n 194 · Phase 3 · secondary NCT01968031
  • 20.2 vs 19.9 20 mg/Day · wk 6 · n 194 · Phase 3 · secondary NCT01968031
  • 20.8 vs 20.1 20 mg/Day · wk 2 · n 194 · Phase 3 · secondary NCT01968031
  • 19.6 vs 19.4 40 mg/Day · wk 12 · n 200 · Phase 3 · secondary NCT01968031
  • 19.9 vs 19.2 40 mg/Day · wk 10 · n 200 · Phase 3 · secondary NCT01968031
  • 20.2 vs 19.9 40 mg/Day · wk 6 · n 200 · Phase 3 · secondary NCT01968031
  • 20.7 vs 20.1 40 mg/Day · wk 2 · n 200 · Phase 3 · secondary NCT01968031
VG081821AC
—Trial running · NCT07725562

MDS-UPDRS Part II, change

istradefylline
—Not posted · NCT00955526
VG081821AC
—Trial running · NCT07725562
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

VG081821AC: no structured comparison results are available for Parkinson's Disease.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. istradefylline: 4 of 4 rows · VG081821AC: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricistradefylline
Dropout rate
9.9%20 mg/Daya
NCT01968031 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
show 2 more results
14%40 mg/Day
NCT01968031 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
—20 mg or 40 mg
NCT02610231 · Phase 3
Discontinued due to AEs
5%20 mg/Daya
NCT01968031 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
show 2 more results
10.6%40 mg/Day
NCT01968031 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
—20 mg or 40 mg
NCT02610231 · Phase 3
Serious AEs
3%20 mg/Daya
NCT01968031 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
show 2 more results
3.9%40 mg/Day
NCT01968031 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
12.6%20 mg or 40 mg
NCT02610231 · Phase 3
Most frequent reported AEs
20 mg/Daya
dyskinesia 11.4% (placebo 6.9%)
fall 6.5% (placebo 4.4%)
insomnia 5% (placebo 2.5%)
NCT01968031 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
show 2 more results
40 mg/Day
dyskinesia 16.4% (placebo 6.9%)
fall 8.7% (placebo 4.4%)
nausea 5.8% (placebo 1%)
NCT01968031 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
20 mg or 40 mg
dyskinesia 18%
fall 12.1%
parkinson's disease 7.9%
NCT02610231 · Phase 3

Notes

  1. aPopulation comparability has not been reviewed for 1 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

istradefylline

OFF Time 4.33 vs 4.83 placebo hours @ 2wk20 mg/Day
absolute change · hours
NCT01968031 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
show 7 more results
3.83 vs 4.17 placebo hours @ 6wk20 mg/Day
NCT01968031 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
3.83 vs 4.33 placebo hours @ 10wk20 mg/Day
NCT01968031 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
4 vs 4.17 placebo hours @ 12wk20 mg/Day
NCT01968031 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
4.08 vs 4.83 placebo hours @ 2wk40 mg/Day
NCT01968031 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
3.83 vs 4.17 placebo hours @ 6wk40 mg/Day
NCT01968031 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
3.5 vs 4.33 placebo hours @ 10wk40 mg/Day
NCT01968031 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
3.83 vs 4.17 placebo hours @ 12wk40 mg/Day
NCT01968031 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
On" Time Without Troublesome Dyskinesia 10.2 vs 9.89 placebo hours @ 2wk20 mg/Day
absolute change · hours
NCT01968031 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
show 7 more results
10.74 vs 10.18 placebo hours @ 6wk20 mg/Day
NCT01968031 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
10.68 vs 10.12 placebo hours @ 10wk20 mg/Day
NCT01968031 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
10.71 vs 10.13 placebo hours @ 12wk20 mg/Day
NCT01968031 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
10.46 vs 9.89 placebo hours @ 2wk40 mg/Day
NCT01968031 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
10.46 vs 10.18 placebo hours @ 6wk40 mg/Day
NCT01968031 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
10.53 vs 10.12 placebo hours @ 10wk40 mg/Day
NCT01968031 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
10.53 vs 10.13 placebo hours @ 12wk40 mg/Day
NCT01968031 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
UPDRS Part III 20.8 vs 20.1 placebo score @ 2wk20 mg/Day
absolute change · score
NCT01968031 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
show 7 more results
20.2 vs 19.9 placebo score @ 6wk20 mg/Day
NCT01968031 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
19.4 vs 19.2 placebo score @ 10wk20 mg/Day
NCT01968031 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
19.7 vs 19.4 placebo score @ 12wk20 mg/Day
NCT01968031 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
20.7 vs 20.1 placebo score @ 2wk40 mg/Day
NCT01968031 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
20.2 vs 19.9 placebo score @ 6wk40 mg/Day
NCT01968031 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
19.9 vs 19.2 placebo score @ 10wk40 mg/Day
NCT01968031 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
19.6 vs 19.4 placebo score @ 12wk40 mg/Day
NCT01968031 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
UPDRS Part 2 10.7 vs 11.1 placebo score @ 2wk20 mg/Day
absolute change · score
NCT01968031 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
show 7 more results
10.5 vs 11 placebo score @ 6wk20 mg/Day
NCT01968031 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
10.8 vs 10.9 placebo score @ 10wk20 mg/Day
NCT01968031 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
10.7 vs 10.9 placebo score @ 12wk20 mg/Day
NCT01968031 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
11.5 vs 11.1 placebo score @ 2wk40 mg/Day
NCT01968031 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
11.8 vs 11 placebo score @ 6wk40 mg/Day
NCT01968031 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
11.6 vs 10.9 placebo score @ 10wk40 mg/Day
NCT01968031 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
11.8 vs 10.9 placebo score @ 12wk40 mg/Day
NCT01968031 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
UPDRS Part 1 1.1 vs 1.4 placebo score @ 2wk20 mg/Day
absolute change · score
NCT01968031 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
show 7 more results
1.3 vs 1.5 placebo score @ 6wk20 mg/Day
NCT01968031 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
1.4 vs 1.5 placebo score @ 10wk20 mg/Day
NCT01968031 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
1.4 vs 1.5 placebo score @ 12wk20 mg/Day
NCT01968031 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
1.3 vs 1.4 placebo score @ 2wk40 mg/Day
NCT01968031 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
1.5 vs 1.5 placebo score @ 6wk40 mg/Day
NCT01968031 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
1.4 vs 1.5 placebo score @ 10wk40 mg/Day
NCT01968031 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
1.4 vs 1.5 placebo score @ 12wk40 mg/Day
NCT01968031 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
UPDRS 32.7 vs 32.6 placebo score @ 2wk20 mg/Day
absolute change · score
NCT01968031 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
show 7 more results
31.9 vs 32.4 placebo score @ 6wk20 mg/Day
NCT01968031 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
31.6 vs 31.6 placebo score @ 10wk20 mg/Day
NCT01968031 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
31.9 vs 31.9 placebo score @ 12wk20 mg/Day
NCT01968031 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
33.6 vs 32.6 placebo score @ 2wk40 mg/Day
NCT01968031 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
33.5 vs 32.4 placebo score @ 6wk40 mg/Day
NCT01968031 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
33 vs 31.6 placebo score @ 10wk40 mg/Day
NCT01968031 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
32.9 vs 31.9 placebo score @ 12wk40 mg/Day
NCT01968031 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
Sleep Time 8.14 vs 8.1 placebo hours @ 2wk20 mg/Day
absolute change · hours
NCT01968031 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
show 7 more results
8.21 vs 8.23 placebo hours @ 6wk20 mg/Day
NCT01968031 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
8.3 vs 8.38 placebo hours @ 10wk20 mg/Day
NCT01968031 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
8.13 vs 8.26 placebo hours @ 12wk20 mg/Day
NCT01968031 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
8.13 vs 8.1 placebo hours @ 2wk40 mg/Day
NCT01968031 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
8.4 vs 8.23 placebo hours @ 6wk40 mg/Day
NCT01968031 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
8.44 vs 8.38 placebo hours @ 10wk40 mg/Day
NCT01968031 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
8.3 vs 8.26 placebo hours @ 12wk40 mg/Day
NCT01968031 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
Awake OFF Time 29.46 vs 30.95 placebo % of time @ 2wk20 mg/Day
absolute value · % of time
NCT01968031 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
show 7 more results
26.31 vs 28.04 placebo % of time @ 6wk20 mg/Day
NCT01968031 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
25.69 vs 28.8 placebo % of time @ 10wk20 mg/Day
NCT01968031 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
26.24 vs 28.62 placebo % of time @ 12wk20 mg/Day
NCT01968031 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
27.45 vs 30.95 placebo % of time @ 2wk40 mg/Day
NCT01968031 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
26.39 vs 28.04 placebo % of time @ 6wk40 mg/Day
NCT01968031 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
25.09 vs 28.8 placebo % of time @ 10wk40 mg/Day
NCT01968031 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
26.51 vs 28.62 placebo % of time @ 12wk40 mg/Day
NCT01968031 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
ON Time Without Troublesome Dyskinesia 64.72 vs 62.99 placebo % of time @ 2wk20 mg/Day
absolute value · % of time
NCT01968031 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
show 7 more results
68.51 vs 65.34 placebo % of time @ 6wk20 mg/Day
NCT01968031 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
68.65 vs 65.33 placebo % of time @ 10wk20 mg/Day
NCT01968031 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
68.17 vs 65.17 placebo % of time @ 12wk20 mg/Day
NCT01968031 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
66.26 vs 62.99 placebo % of time @ 2wk40 mg/Day
NCT01968031 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
67.55 vs 65.34 placebo % of time @ 6wk40 mg/Day
NCT01968031 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
68.17 vs 65.33 placebo % of time @ 10wk40 mg/Day
NCT01968031 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
67.64 vs 65.17 placebo % of time @ 12wk40 mg/Day
NCT01968031 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
BDI 7.5 vs 7.9 placebo score @ 12wk20 mg/Day
absolute change · score
NCT01968031 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
show 1 more result
8.3 vs 7.9 placebo score @ 12wk40 mg/Day
NCT01968031 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
OFF Time 4.6%istradefylline 20mg/day
absolute change · percentage points
No placebo or comparator arm
NCT00199407 · Phase 3 · sponsor-reported, not registry data

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: istradefylline's landscape · VG081821AC's landscape